A Phase 3 interventional study of SD-809 and Placebo in Tardive Dyskinesia, sponsored by Auspex Pharmaceuticals, Inc.. Completed at 106 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Auspex Pharmaceuticals, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.
Among the 31 studies in Tardive Dyskinesia with a site in United States, this one is the 3rd largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2014, is one of 6 in phase 3, and was the 14th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
Neurocrine Biosciences · Sites in United States, Bulgaria, Puerto Rico
Ages 18–75
Neurocrine Biosciences · Sites in United States
Ages 18+
iRxReminder · Sites in United States
Ages 18+
Corporal Michael J. Crescenz VA Medical Center · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 8
First in 1996; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 298 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 89 across the 27 interventional studies, 70 across the 3 observational. Of the 21 that completed or were terminated, 14 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Auspex Pharmaceuticals, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Auspex Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Teva Pharmaceutical Industries, Ltd. has 3 studies filed under Tardive Dyskinesia — fewer than ten, so there is no comparison to draw.
2 of the studies in Tardive Dyskinesia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07365462Neurocrine BiosciencesEfficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | 2027-02 |
| NCT06997198University Hospitals Cleveland Medical CenterDeutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Tardive Dyskinesia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo tablets taken twice daily for 12 weeks.
Drug: Placebo
SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
Drug: SD-809
SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
Drug: SD-809
SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
Drug: SD-809
SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
Also known as: deutetrabenzine, Austedo
Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)
AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of dopamine receptor antagonist (DRAs) as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.
Time frame: Day 0 (Baseline), Weeks 2, 4, 8 and 12
Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)
The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% confidence interval (CI) was calculated with the Wilson (score) confidence limits.
Time frame: Week 12
Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12
The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 - 96. Negative change from baseline scores indicate improvement. For patients with missing data at week 12, the baseline or last available value was used as the week 12 value.
Time frame: Day 0 (Baseline), Week 12
Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)
The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% CI was calculated with the Wilson (score) confidence limits.
Time frame: Week 12
Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12
Responders who had a 50% or greater improvement in total motor modified AIMS at Week 12 as compared to baseline were reported as a percentage of participants with an outcome at Week 12. The responder 95% CI is calculated with the Wilson (score) confidence limits. AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement.
Time frame: Day 0 (Baseline), Week 12
Percent Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model for Repeated Measures (MMRM)
AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.
Time frame: Day 0 (Baseline), Weeks 2, 4, 8 and 12
Cumulative Percentage of Responders Based on Change in in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Recorded in Incremental Steps of 10 Percentage Points
AIMS is an assessment tool used to detect and follow the severity of TD over time, composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. Participants with missing data are classified as non-responders. The responder 95% CI is calculated with the Wilson (score) confidence limits. If any of the expected cell counts are \< 5, exact Clopper Pearson limits are presented. Data report the percentage of participants who responded to the percentage improvement indicated in each row.
Time frame: Day 0 (Baseline), Week 12
Participants With Adverse Events During the Overall Treatment Period
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
Time frame: Day 1 to Week 12
This study was performed at 75 study centers (38 in the US, 19 in Poland, 7 in Hungary, 6 in the Czech Republic, 3 in Slovakia, and 2 in Germany) by 75 investigators; 298 patients were enrolled.
| Milestone | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Started | 74 | 75 | 74 | 75 |
| Safety population | 72 | 74 | 73 | 74 |
| Modified intent to treat pop (mitt) | 58 | 60 | 49 | 55 |
| Completed | 67 | 67 | 65 | 65 |
| Not completed | 7 | 8 | 9 | 10 |
| Withdrew: Adverse event | 2 | 4 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 4 |
| Withdrew: Noncompliance | 1 | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 4 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
AIMS is an assessment tool used to detect and follow the severity of tardive dyskinesia (TD) over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of dopamine receptor antagonist (DRAs) as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.
| units on a scale | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) | -1.4 ± 0.41 | -2.1 ± 0.42 | -3.2 ± 0.45 | -3.3 ± 0.42 |
The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% confidence interval (CI) was calculated with the Wilson (score) confidence limits.
| percentage of participants | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC) | 26 (16.3 to 38.4) | 28 (18.5 to 40.8) | 49 (35.6 to 62.5) | 44 (31.4 to 56.7) |
The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the mCDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 - 96. Negative change from baseline scores indicate improvement. For patients with missing data at week 12, the baseline or last available value was used as the week 12 value.
| units on a scale | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Change in the Modified Craniocervical Dystonia Questionnaire (mCDQ-24) Total Score From Baseline to Week 12 | -7.1 ± 2.06 | -5.8 ± 2.03 | -10.2 ± 2.21 | -10.7 ± 2.04 |
The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures. The success 95% CI was calculated with the Wilson (score) confidence limits.
| percentage of participants | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Percentage of Patients Considered a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC) | 31 (20.6 to 43.8) | 23 (14.4 to 35.4) | 45 (31.9 to 58.7) | 40 (28.1 to 53.2) |
Responders who had a 50% or greater improvement in total motor modified AIMS at Week 12 as compared to baseline were reported as a percentage of participants with an outcome at Week 12. The responder 95% CI is calculated with the Wilson (score) confidence limits. AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement.
| percentage of participants | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Percentage of Participants Who Had a 50% or Greater Reduction in Total Motor Abnormal Involuntary Movement Scale (AIMS) From Baseline to Week 12 | 12 (6.0 to 22.9) | 13 (6.9 to 24.2) | 35 (22.9 to 48.7) | 33 (21.8 to 45.9) |
AIMS is an assessment tool used to detect and follow the severity of TD over time. AIMS is composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. MMRM with treatment group, visit, treatment group-by-visit interaction, and baseline use of DRAs as fixed effects and the baseline value as a covariate. The model was fit using an unstructured covariance structure.
| percentage of baseline | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Percent Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model for Repeated Measures (MMRM) | -11.6 ± 4.32 | -20.0 ± 4.34 | -31.9 ± 4.73 | -33.1 ± 4.38 |
AIMS is an assessment tool used to detect and follow the severity of TD over time, composed of 12 clinician-administered and scored items. The exam was digitally video recorded using a standard protocol, and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, as well as extremity and truncal dyskinesia (the total motor AIMS score). Ratings were based on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe) for a total scale of 0-28. A negative change from baseline score indicates improvement. Participants with missing data are classified as non-responders. The responder 95% CI is calculated with the Wilson (score) confidence limits. If any of the expected cell counts are \< 5, exact Clopper Pearson limits are presented. Data report the percentage of participants who responded to the percentage improvement indicated in each row.
| percentage of participants | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| 10% Improvement | 50 (37.5 to 62.5) | 62 (49.0 to 72.9) | 67 (53.4 to 78.8) | 71 (57.9 to 81.2) |
| 20% Improvement | 40 (28.1 to 52.5) | 47 (34.6 to 59.1) | 59 (45.2 to 71.8) | 60 (46.8 to 71.9) |
| 30% Improvement | 31 (20.6 to 43.8) | 32 (21.3 to 44.2) | 49 (35.6 to 62.5) | 49 (36.4 to 61.9) |
| 40% Improvement | 16 (8.4 to 26.9) | 23 (14.4 to 35.4) | 45 (31.9 to 58.7) | 40 (28.1 to 53.2) |
| 50% Improvement | 12 (6.0 to 22.9) | 13 (6.9 to 24.2) | 35 (22.9 to 48.7) | 33 (21.8 to 45.9) |
| 60% Improvement | 5 (1.8 to 14.1) | 7 (2.6 to 15.9) | 20 (11.5 to 33.6) | 18 (10.2 to 30.3) |
| 70% Improvement | 2 (0.0 to 9.2) | 3 (0.4 to 11.5) | 12 (4.6 to 24.8) | 16 (7.8 to 28.8) |
| 80% Improvement | 2 (0.0 to 9.2) | 2 (0.0 to 8.9) | 2 (0.1 to 10.9) | 13 (5.3 to 24.5) |
| 90% Improvement | 2 (0.0 to 9.2) | 0 (0.0 to 6.0) | 0 (0.0 to 7.3) | 5 (1.1 to 15.1) |
An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
| Participants | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Overall Treatment Period: any AE | 34 | 36 | 32 | 38 |
| Overall Treatment Period: SAE | 4 | 2 | 6 | 4 |
| Overall Treatment Period: Severe AE | 2 | 2 | 4 | 1 |
| Overall Treatment Period: treatment-related AE | 19 | 13 | 11 | 18 |
| Dose reduction because of AE | 0 | 0 | 1 | 3 |
| Dose suspension because of AE | 2 | 3 | 1 | 1 |
| Withdrawn from study because of AE | 2 | 4 | 2 | 3 |
Collected over Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/72 (0%) | 4/72 (5.6%) | 14/72 (19.4%) |
| SD-809 12 mg/Day | 0/74 (0%) | 2/74 (2.7%) | 9/74 (12.2%) |
| SD-809 24 mg/Day | 1/73 (1.4%) | 6/73 (8.2%) | 9/73 (12.3%) |
| SD-809 36 mg/Day | 1/74 (1.4%) | 4/74 (5.4%) | 10/74 (13.5%) |
| Event | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/72 | 0/74 | 0/73 | 0/74 |
| Pancreatic massGastrointestinal disorders | 1/72 | 0/74 | 0/73 | 0/74 |
| Head injuryInjury, poisoning and procedural complications | 1/72 | 0/74 | 0/73 | 0/74 |
| Neuroendocrine carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/72 | 0/74 | 0/73 | 0/74 |
| Bipolar disorderPsychiatric disorders | 1/72 | 0/74 | 0/73 | 0/74 |
| Sudden cardiac deathGeneral disorders | 0/72 | 0/74 | 1/73 | 0/74 |
| AppendicitisInfections and infestations | 0/72 | 0/74 | 1/73 | 0/74 |
| CellulitisInfections and infestations | 0/72 | 0/74 | 1/73 | 0/74 |
| PneumoniaInfections and infestations | 0/72 | 0/74 | 1/73 | 1/74 |
| DepressionPsychiatric disorders | 0/72 | 0/74 | 1/73 | 0/74 |
| Event | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 7/72 | 1/74 | 1/73 | 1/74 |
| DiarrhoeaGastrointestinal disorders | 2/72 | 1/74 | 3/73 | 5/74 |
| HeadacheNervous system disorders | 4/72 | 5/74 | 2/73 | 5/74 |
| NasopharyngitisInfections and infestations | 1/72 | 4/74 | 3/73 | 2/74 |
The Safety Population was a subset of randomized participants and included all patients who were administered study drug (N=293).
| Age, Continuous(years) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| Mean | 54.6 ± 12.06 | 57.0 ± 9.95 | 55.6 ± 11.34 | 58.3 ± 11.55 | 56.4 ± 11.27 |
| Sex: Female, Male(Participants) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| Female | 37 | 42 | 41 | 42 | 162 |
| Male | 35 | 32 | 32 | 32 | 131 |
| Race/Ethnicity, Customized(Participants) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 | 4 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 15 | 19 | 10 | 56 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 59 | 58 | 54 | 61 | 232 |
| Other | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| Hispanic or latino | 7 | 6 | 3 | 7 | 23 |
| Not hispanic or latino | 64 | 64 | 69 | 65 | 262 |
| Not reported | 0 | 3 | 1 | 1 | 5 |
| Unknown | 1 | 1 | 0 | 1 | 3 |
| Weight(kg) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| Mean | 82.8 ± 18.51 | 80.8 ± 21.00 | 86.8 ± 18.79 | 78.5 ± 17.56 | 82.2 ± 19.16 |
| Height(cm) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| Mean | 168.3 ± 9.25 | 167.7 ± 10.68 | 168.7 ± 9.39 | 167.6 ± 10.55 | 168.1 ± 9.96 |
| Body Mass Index(kg/m^2) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| Mean | 29.18 ± 6.128 | 28.69 ± 6.814 | 30.64 ± 7.021 | 27.99 ± 6.178 | 29.12 ± 6.587 |
| Education Level(Participants) | Placebo | SD-809 12 mg/Day | SD-809 24 mg/Day | SD-809 36 mg/Day | Total |
|---|---|---|---|---|---|
| <= 12 years | 40 | 44 | 44 | 39 | 167 |
| > 12 years | 32 | 30 | 29 | 35 | 126 |
4 further baseline measures are reported on the registry.
Showing the first 100 of 106 sites across 6 countries. Choose a country and city above to see the rest.
Ran from Oct 2014 to primary completion in Aug 2016, 21 months.
Results were first posted in Apr 2018, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deutetrabenazine
Auspex Pharmaceuticals, Inc. →